ClinicalTrials.gg
Not yet recruitingNCT06926400Updated Apr 13, 2025

The Effectiveness and Safety of the Coronary Artery Serrated Cutting Balloon Dilation Catheter in the Pre-dilation of Coronary Artery Stenosis Lesions

An interventional study of Coronary artery sawtooth cutting balloon dilation catheter and Cutting balloon catheter in Coronary Artery Disease, sponsored by JW Medical Systems Ltd. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by JW Medical Systems Ltd (part of Blue Sail Medical Co., Ltd.) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. — 8 open to participants now, 11 under way, none of them phase 3. Coronary Artery Disease · Blue Sail Medical Co., Ltd..

Planned enrollment
11th of 16
182 · median 200
Started
2025
with 1 other
No phase
16 of 23
7 open now
Primary completion
2025-12
later than 5 of 10 live
Registered
22nd of 23
by date

Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 16 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 22nd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., or all of them as a file.
02

Study summary

To evaluate the effectiveness and safety of the coronary serrated cutting balloon dilation catheter for the pre-dilation of coronary artery stenosis lesions.

Read the detailed description

This study is a prospective, multicenter, randomized controlled, non-inferiority designed clinical trial. It is planned to enroll a total of 182 eligible subjects from multiple research centers. The subjects will be randomly assigned to the experimental group (n = 91) and the control group (n = 91) in a 1:1 ratio. All subjects will undergo immediate coronary angiography after percutaneous transluminal coronary angioplasty (PTCA) to evaluate the success rate of the device.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ① The age is between 18 and 80 years old (including the boundary values), and the subjects are male or non-pregnant female.

    • Have single or multiple coronary artery lesions and diagnosed ischemic heart disease (for example: stable angina pectoris, unstable angina pectoris, old myocardial infarction or asymptomatic myocardial ischemia).

      • There are coronary artery stenosis lesions confirmed by coronary angiography, which are suitable for percutaneous coronary intervention. The coronary artery stenosis is ≥ 70% (by visual estimation); or ≥ 50% (by visual estimation) and accompanied by evidence of ischemia, and the TIMI blood flow is ≥ Grade 1.

        • There are de novo or restenosis lesions in the coronary arteries of autologous or bypass graft vessels, and interventional treatment is required.

          • The visually estimated reference vessel diameter of the target lesion is 2.0mm - 4.0mm, and the lesion length is ≤ 20mm.

            • When there are multiple lesions that need to be treated, only one coronary artery lesion is selected as the target lesion, and the non-target lesions must be located on different vascular branches.

Be able to understand the purpose of the study, voluntarily participate and sign the form, and be able to and willing to accept the follow-up as specified in this trial.

Exclusion criteria

Exclusion Criteria:

  • General Exclusion Criteria

    • Patients with (NYHA) Class IV heart failure.

      • Patients with to anti - and anticoagulant therapy and are unable to receive anticoagulant treatment.

        • Patients who have had any myocardial infarction within one week.

          • Patients with an allergic reaction to contrast agents. ⑤ Patients with severe renal failure, with a serum creatinine level > 2.0 mg/dl (177 μmol/L).

            • Patients who have undergone heart transplantation.

              • Patients who have had active peptic ulcer or active gastrointestinal bleeding within 1 month before surgery.

                ⑧ Patients who have had a stroke or within 3 months before surgery.

                • Pregnant or lactating patients. ⑩ Patients who are currently participating in any other clinical trials. ⑪ Patients whom the investigator deems unsuitable for enrollment. Exclusion Criteria Related to the Target Lesion (Detected by Coronary Angiography)
    • Tortuous lesions or lesions with an angulation of ≥ 45 degrees at the lesion site.

      • Lesions at the ostium with a distance of ≤ 2 mm from the left main coronary artery.

        • Unprotected left main coronary artery lesions. ④ Coronary angiography shows the presence of thrombus. ⑤ Before using the test device or the control device, the target lesion has a dissection of Type C or higher.

Target lesions that require treatment with coronary atherectomy or special balloons (such as scored balloons, spiked balloons, shock - wave lithotripsy systems, and cutting balloons of other brands).

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Coronary Artery Serrated Cutting Balloon Dilatation Catheter (Shandong JW Medical Products Co., Ltd.

    Device: Coronary artery sawtooth cutting balloon dilation catheter

  • Active comparator
    Cutting Balloon Catheter

    Device: Cutting balloon catheter

Interventions

  • DeviceCoronary artery sawtooth cutting balloon dilation catheter

    Ninety-one subjects who met the inclusion criteria were enrolled and randomly assigned to the treatment group using a coronary artery sawtooth cutting balloon dilation catheter.

  • DeviceCutting balloon catheter

    Ninety-one subjects who met the inclusion criteria were enrolled and randomly assigned to the treatment group using a cutting balloon catheter.

06

What researchers measure

Primary outcomes

  1. Device Procedural Success Rate

    Time frame: one hour

Secondary outcomes

  1. Clinical treatment success rate

    Time frame: one hour

  2. acute lumen gain,ALG

    Immediate lumen gain is defined as: ALG = the immediate minimum lumen diameter after balloon dilation - the minimum lumen diameter before the operation.

    Time frame: one hour

  3. The incidence of the composite endpoint of target lesion failure (TLF) within 30 days after surgery

    Time frame: 30 days

  4. The incidence of patient-related cardiovascular clinical composite endpoint (POCE) within 30 days after surgery

    Time frame: 30 days

  5. The incidence of major adverse cardiac events (MACE) within 30 days after surgery

    Time frame: 30 days

  6. Evaluation of Device Performance

    CRF

    Time frame: one hour

  7. The incidence rate of medical device-related complications

    Time frame: one hour

  8. The incidence rate of device defects

    Time frame: one hour

  9. The incidence rate of adverse events and serious adverse events

    Time frame: thirty days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Dec 2025, 8 months later.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 8 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 13, 2025
StartEst.
Apr 10, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
Mar 30, 2026
Last update
Apr 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06926400
Responsible party
Sponsor
First posted
Apr 13, 2025
Start date
Apr 10, 2025 (estimated)
Primary completion
Dec 30, 2025 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Apr 13, 2025

Study contacts

WangYang
Contact
yang.wang@jwmsgrp.com
13366024088
Yu Bo
principal investigator · The Second Affiliated Hospital of Harbin Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion